Core Viewpoint - The introduction of the anti-aging product "瑞拓龄" by Guoyao, priced between 2000 to over 7000 yuan, has sparked debate on whether longevity drugs are merely a "wealth tax" for the rich, with increasing interest from elite groups like entrepreneurs and executives [1][11] Group 1: Historical Context of Longevity Pursuits - Throughout history, the pursuit of longevity has been a constant theme, with ancient Chinese emperors and Western aristocrats engaging in various dubious practices to extend their lives [2][4] - The historical use of bloodletting as a common medical practice illustrates how wealthy individuals often fell victim to ineffective treatments, which later became known as a "wealth tax" due to their lack of scientific basis [5][7] Group 2: Scientific Advances in Aging Research - Recent decades have seen significant breakthroughs in aging research, particularly with the discovery that inhibiting mTOR can extend lifespan in mice, leading to advancements in anti-aging products [8][9] - The development of the "希诺裂" (Senolytic) technology by the Mayo Clinic has shown promise in clearing aging cells, further advancing the field of aging intervention [9] - Companies like Eli Lilly, Roche, and Senogen have begun to invest in aging intervention products, with Senogen leading the way in product development based on mTOR inhibition and Senolytic pathways [9][11] Group 3: Market Implications and Future Outlook - The partnership between Guoyao and Senogen to introduce 瑞拓龄 in China indicates a shift towards more scientifically-backed anti-aging products in a market previously filled with dubious alternatives [11][14] - The ongoing debate about whether longevity drugs are a "wealth tax" for the rich may soon find resolution as the market evolves with more credible scientific support [14]